98 related articles for article (PubMed ID: 3353076)
1. High doses of methylprednisolone with or without alizapride in the prevention of cisplatin-induced emesis. A randomized, double-blind, crossover study.
Giaccone G; Bertetto O; Secat MA; Calciati A
Oncology; 1988; 45(2):74-8. PubMed ID: 3353076
[TBL] [Abstract][Full Text] [Related]
2. A prospective randomized double-blind crossover study comparing the antiemetic activity of alizapride and metoclopramide in patients receiving cisplatin chemotherapy.
Basurto C; Roila F; Del Favero A; Ballatori E; Minotti V; Tonato M
Cancer Invest; 1988; 6(5):475-9. PubMed ID: 3063335
[TBL] [Abstract][Full Text] [Related]
3. Antiemetic efficacy of alprazolam in the combination of metoclopramide plus methylprednisolone. Double-blind randomized crossover study in patients with cisplatin-induced emesis.
Mori K; Saito Y; Tominaga K
Am J Clin Oncol; 1993 Aug; 16(4):338-41. PubMed ID: 8392288
[TBL] [Abstract][Full Text] [Related]
4. A comparison of ondansetron with alizapride plus methylprednisolone in the control of cisplatin-induced emesis. The French Pneumology Group for the Ondansetron Study.
Depierre A; Lebeau B; d'Allens H
Oncology; 1992; 49(4):305-11. PubMed ID: 1387930
[TBL] [Abstract][Full Text] [Related]
5. Improved control of cisplatin-induced emesis with a combination of high doses of methylprednisolone and metoclopramide: a single-blind randomized trial.
Bécouarn Y; Nguyen BB; David M; Lakdja F; Brunet R; Chauvergne J
Eur J Cancer Clin Oncol; 1986 Dec; 22(12):1421-4. PubMed ID: 3595666
[TBL] [Abstract][Full Text] [Related]
6. High-dose alizapride versus high-dose domperidone: a double-blind comparative study in the management of cis-platinum-induced emesis.
Huys J; Troch M; Bourguignon RP; Smets P
Curr Med Res Opin; 1985; 9(6):400-6. PubMed ID: 3886305
[TBL] [Abstract][Full Text] [Related]
7. The antiemetic activity of high-dose alizapride and high-dose metoclopramide in patients receiving cancer chemotherapy: a prospective, randomized, double-blind trial.
Joss RA; Galeazzi RL; Bischoff AK; Pirovino M; Ryssel HJ; Brunner KW
Clin Pharmacol Ther; 1986 Jun; 39(6):619-24. PubMed ID: 3519041
[TBL] [Abstract][Full Text] [Related]
8. Comparative effects of intravenously administered alizapride and prochlorperazine in cisplatin-induced emesis.
Roché H; Hyman G; Nahas G; Stoopler M; Ellison R; Desjardins R
Cancer Invest; 1987; 5(2):89-93. PubMed ID: 3607576
[TBL] [Abstract][Full Text] [Related]
9. Dexamethasone plus ondansetron versus dexamethasone plus alizapride in the prevention of emesis induced by cisplatin-containing chemotherapies for urological cancers.
Nicolai N; Mangiarotti B; Salvioni R; Piva L; Faustini M; Pizzocaro G
Eur Urol; 1993; 23(4):450-6. PubMed ID: 8335048
[TBL] [Abstract][Full Text] [Related]
10. Alizapride alone or alizapride-dexamethasone compared with metoclopramide-dexamethasone in patients at high risk of acute emesis after cisplatin. A randomized cross-over study.
Pollera CF; Nardi M; Marolla P; Calabresi F
Acta Oncol; 1991; 30(6):725-9. PubMed ID: 1958393
[TBL] [Abstract][Full Text] [Related]
11. Randomized trial for the control of acute vomiting in cisplatin-treated patients: high-dose metoclopramide with dexamethasone and lorazepam as adjuncts versus high-dose alizapride plus dexamethasone and lorazepam. Study of the incidence of delayed emesis.
Moreno I; Rosell R; Abad-Esteve A; Barnadas A; Carles J; Ribelles N
Oncology; 1991; 48(5):397-402. PubMed ID: 1745488
[TBL] [Abstract][Full Text] [Related]
12. Anti-emetic effect of high-dose metoclopramide vs alizapride--a randomised crossover study.
Seng KT; Tiong CE; Hiang TC
Br J Clin Pharmacol; 1994 Sep; 38(3):282-4. PubMed ID: 7826833
[TBL] [Abstract][Full Text] [Related]
13. Tropisetron plus haloperidol to ameliorate nausea and vomiting associated with high-dose alkylating agent cancer chemotherapy.
Bregni M; Siena S; Di Nicola M; Bonadonna G; Gianni AM
Eur J Cancer; 1991; 27(5):561-5. PubMed ID: 1828962
[TBL] [Abstract][Full Text] [Related]
14. A randomized trial comparing alizapride alone or with dexamethasone vs a metoclopramide-dexamethasone combination for emesis induced by moderate-dose cisplatin.
Pollera CF; Nardi M; Marolla P; Carlini P
Cancer Chemother Pharmacol; 1987; 19(4):335-8. PubMed ID: 3297376
[TBL] [Abstract][Full Text] [Related]
15. The antiemetic activity of high-dose metoclopramide and high-dose alizapride in combination with lorazepam in patients receiving cancer chemotherapy. A prospective, randomized, double-blind study.
Molino A; Guglielmo L; Azzolini ME; Biondani P; Capelli MC; Grandinetti A; Griso C; Martinelli G; Martini N; Zanotti R
Oncology; 1991; 48(2):111-5. PubMed ID: 1997932
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of high-dose i.v. alizapride in prevention of cisplatin-induced emesis.
Canal P; Roche H; Pasquier M; Bugat R; Berg D; Soula G; Carton M
Fundam Clin Pharmacol; 1987; 1(3):213-7. PubMed ID: 3428840
[TBL] [Abstract][Full Text] [Related]
17. [Granisetron versus granisetron plus methylprednisolone in the prevention of chemotherapy induced nausea and vomiting--in adjuvant chemotherapy, including CDDP against gastric cancer].
Kurita A; Takashima S; Nakata M; Kubo Y; Saiki T; Ohsumi S; Yokoyama N; Tanada M; Takiyama W; Saeki H
Gan To Kagaku Ryoho; 1997 Jan; 24(1):49-54. PubMed ID: 9020945
[TBL] [Abstract][Full Text] [Related]
18. Crossover comparison of the antiemetic efficacy of nabilone and alizapride in patients with nonseminomatous testicular cancer receiving cisplatin therapy.
Niederle N; Schütte J; Schmidt CG
Klin Wochenschr; 1986 Apr; 64(8):362-5. PubMed ID: 3009962
[TBL] [Abstract][Full Text] [Related]
19. Protection from nausea and vomiting in cisplatin-treated patients: high-dose metoclopramide combined with methylprednisolone versus metoclopramide combined with dexamethasone and diphenhydramine: a study of the Italian Oncology Group for Clinical Research.
Roila F; Tonato M; Basurto C; Picciafuoco M; Bracarda S; Donati D; Malacarne P; Monici L; Di Costanzo F; Patoia L
J Clin Oncol; 1989 Nov; 7(11):1693-700. PubMed ID: 2681556
[TBL] [Abstract][Full Text] [Related]
20. Phase II trial of ramosetron plus dexamethasone in the prevention of cisplatin-induced nausea and vomiting.
Voravud N; Sriuranpong V
J Med Assoc Thai; 2005 Dec; 88(12):1790-6. PubMed ID: 16518975
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
